<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299922</url>
  </required_header>
  <id_info>
    <org_study_id>Csa-LES</org_study_id>
    <nct_id>NCT01299922</nct_id>
  </id_info>
  <brief_title>Clinical Trial Treatment in Lupus Nephritis</brief_title>
  <acronym>Csa-LES</acronym>
  <official_title>Phase III, Open, Randomized, Parallel-group Clinical Trial, to Evaluate the Efficacy and Safety of Treatment With Prednisone, Cyclosporine, Mycophenolic Acid Versus Prednisone and Mycophenolic Acid in Lupus Nephritis Type III-IV-V.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Fundación Alcorcón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario 12 de Octubre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infanta Sofia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Infanta Leonor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Reina Sofia de Cordoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Regional Universitario Carlos Haya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of the Nuestra Señora de Candelaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario de Guadalajara. Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Pedro Alcantara. Caceres. Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Juan Canalejo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Fundación Alcorcón</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of lupus nephritis with cyclophosphamide and steroids changed the prognosis of
      lupus nephritis in the early '80s. In recent years, alternative regimens have appeared in
      both the induction and maintenance with similar results at least to those offered by the
      classic pattern and possibly with fewer side effects, especially for long term. The
      association of prednison and mycophenolate has created large expectations to that effect, and
      is part of first-line therapeutic arsenal of lupus nephritis type III, IV and V.

      Despite the significant advances that have led to these treatments, the likelihood of
      complete remission after six months remains, according to the series of 8-13% and partial
      remission do not exceed 60% in papers published. In the last year, two articles have been
      published supporting the use of triple therapy (prednisone, mycophenolate, cyclosporine) in
      poor prognosis of lupus nephritis with hopefully better results than those obtained
      previously. In this study we try to compare the effectiveness of triple therapy, the therapy
      is now considered standard (prednisone, mycophenolate) in patients with lupus nephritis type
      III-IV-V
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      asd
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IT was impossible to find patients
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of complete remissions, between the triple therapy with cyclosporine-prednisone-mycophenolic acid and conventional therapy with mycophenolic acid-prednisone as induction therapy in patients with lupus nephritis type III-IV-V</measure>
    <time_frame>36 months</time_frame>
    <description>Complete remission:
Proteinuria &lt; 0.3 g/24h
Albumin normal
eGFR &gt; 60 mL/min/1.73 m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the number of partial and complete remissions, between triple therapy with prednisone, cyclosporine, mycophenolic acid and prednisone-mycophenolic acid.</measure>
    <time_frame>36 months</time_frame>
    <description>Partial remission: Proteinuria 0.3-3.5 g/24 hours, with a decrease &gt; 50% over basal, stable renal function and albumin normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of patients with adverse effects</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate (%) of decline of proteinuria in two groups</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the decrease in GFR (ml/min/1.73m2) in both groups</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>cyclosporine+mycophenolic acid+prednison</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mycophenolic acid + prednison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mycophenolic acid+prednison 106 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine +mycophenolic acid+prednison</intervention_name>
    <description>Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks</description>
    <arm_group_label>cyclosporine+mycophenolic acid+prednison</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid + prednison</intervention_name>
    <description>Mycophenolic Acid + prednison for 106 weeks</description>
    <arm_group_label>mycophenolic acid + prednison</arm_group_label>
    <other_name>Conventional therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Patients diagnosed SLE with renal type III-IV-V confirmed by renal biopsy done in the
             last 6 months

          -  Proteinuria &gt; 2 g/24 hours and hematuria (&gt; 5 h / field)

          -  MDRD4 eGFR &gt; 60 ml/min/1.73m2

          -  Participant is willing and able to give informed consent for participation in the
             study

        Exclusion Criteria:

          -  Central nervous system LES involvement or any other vital organ

          -  Active infection

          -  Use of mycophenolic acid, mycophenolate mofetil, cyclosporine or tacrolimus in the
             last 6 months

          -  No adherence

          -  Women of childbearing age not using appropriate contraceptive methods.

          -  Positive pregnancy test

          -  Anasarca

          -  Malignancy or cancer history (except basal cell skin carcinomas)

          -  Patient participating in another study with an investigational drug or have
             participated within 28 days prior to entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernandez Juarez Gema, MD Ph</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Fundación Alcorcón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Praga Terente Manuel, MD Ph</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Doce de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2015</last_update_posted>
  <responsible_party>
    <name_title>Manuel Praga Terente</name_title>
    <organization>Hospital Universitario Doce de Octubre Madrid Spain</organization>
  </responsible_party>
  <keyword>Lupus nephritis</keyword>
  <keyword>Therapy</keyword>
  <keyword>Cyclosporin</keyword>
  <keyword>Mycophenolic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

